Mar 4th News Unbelievable Ground Floor - Tumors 7 Times Smaller !!!
IGT Pharma Inc - News Release
Anti-cancer drug test results
IGT Pharma Inc
IGT
Shares issued 6581332
1997-03-03 close $0.68
Tuesday Mar 4 1997
News Release
Mr Bruce Schmidt reports
Pre-clinical studies conducted at the BC Cancer Agency using
Anhydrovinblastine (AVLB), the company's patented anti cancer drug, have
shown excellent preliminary results in reducing tumors relating to human
lung cancer. In a comparative study with Navelbine, Glaxo's successful
anti-cancer drug, it was found that after 23 days, tumors treated with AVLB
were seven times smaller than those treated with Navelbine.
In comparison to a selection of other drugs used to treat cancer, AVLB has
proved itself to be highly effective on a range of tumor types while showing
generally reduced toxic side effects.
AVLB, In its final stages of pre-clinical assessment, is scheduled for phase I
clinical trials later this year. IGT is currently in the process of confirming all
relevant data pertaining to AVLB in preparation for the clinical trials
application.
(c) Copyright 1997 Canjex Publishing Ltd.
canada-stockwatch.com
_______________________________________________________________________
IGT International Growth Technologies - News Release
IRAP grant for Etoposide development
IGT International Growth Technologies
IGT
Shares issued 6261332
1997-02-25 close $0.51
Tuesday Feb 25 1997
News Release
Mr Bruce Schmidt reports
The National Research Council - IRAP program has extended the company's
existing grant for development work on the synthesis of the generic
anti-cancer drug, Etoposide. Etoposide, one of the world's most successful
cancer drugs for the treatment of solid tumors, has an annual market of
approximately $400 million. Etoposide is now only extracted from plants and
therefore has an expensive cost base. The company's technical focus will be
to develop the first synthetic production alternative using only common
starting materials. Progress to date has been extremely encouraging and
will allow the company to file patent applications within the next two to three
months. Following patent and production scale-up activities, the company
will approach its existing contacts in the pharmaceutical industry to arrange
for joint venture or licencing of distribution rights. |
